Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform

Sightera Biosciences , a Belgian techbio company using generative AI to develop novel small-molecule therapies, has raised €3 million in a pre-seed funding round led by Entourage, Anacura and QBIC. A spin-off from the University of Antwerp and Antwerp University Hospital (UZA), Sightera is developing an AI-native drug discovery platform focused on oncology and fibrosis. Unlike many AI drug discovery companies that rely on public or generic datasets, Sightera trains its models using proprietary d